Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599134 | 0.89 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL5599871 | 0.82 | ZDHHC2 (0.38) | ALDH1A1FAAHBCHEACHE | |
| SCHEMBL5599876 | 0.82 | ZDHHC2 (0.38) | ALDH1A1FAAHBCHEACHE | |
| SCHEMBL5599686 | 0.81 | ASAH1 (0.40) | ALDH1A1 | |
| SCHEMBL5599683 | 0.81 | ASAH1 (0.40) | ALDH1A1 | |
| SCHEMBL5599701 | 0.79 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL5599699 | 0.79 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL5598968 | 0.77 | MEN1 (0.45) | MAPK1EPHX2 | |
| SCHEMBL7521457 | 0.67 | MTNR1A (0.44) | L3MBTL1EPHX2MTNR1AMTNR1B | |
| SCHEMBL5599769 | 0.67 | CPB2 (0.47) | TSHRFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282605-B2 | Optically active 2-allylcarboxylic acid derivative and process for producing the same | KANEKA CORPORATION (JP) | 2007-10-16 | — | — | US | disclosed |
| US-20060223152-A1 | Optically active 2-allylcarboxylic acid derivative and process for producing the same | KANEKA CORPORATION (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1650187-A1 | OPTICALLY ACTIVE 2-ALLYLCARBOXYLIC ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | KANEKA CORPORATION (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223152-A1 | Optically active 2-allylcarboxylic acid derivative and process for producing the same | APEH, NAAA, AADAC | ALDH1A1 353/4885TSHR 4246/4885MAPK1 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.